Exploiting Tumor Aneuploidy As a Biomarker and Therapeutic Target in Patients Treated with Immune Checkpoint Blockade

Overview

Journal NPJ Precis Oncol

Publisher Springer Nature

Specialty Oncology

Date 2024 Jan 3

PMID 38167869

Authors

Liam F Spurr

Sean P Pitroda

Affiliations

Soon will be listed here.

Citing Articles

Current state and promise of user-centered design to harness explainable AI in clinical decision-support systems for patients with CNS tumors.

Prince E, Mirsky D, Hankinson T, Gorg C Front Radiol. 2025; 4:1433457.

PMID: 39872709 PMC: 11769936. DOI: 10.3389/fradi.2024.1433457.

The tumour histopathology "glossary" for AI developers.

Mandal S, Baker A, Graham T, Brautigam K PLoS Comput Biol. 2025; 21(1):e1012708.

PMID: 39847582 PMC: 11756763. DOI: 10.1371/journal.pcbi.1012708.

Diagnostic impact of DNA methylation classification in adult and pediatric CNS tumors.

Lebrun L, Gilis N, Dausort M, Gillard C, Rusu S, Slimani K Sci Rep. 2025; 15(1):2857.

PMID: 39843975 PMC: 11754448. DOI: 10.1038/s41598-025-87079-4.

Why implementing machine learning algorithms in the clinic is not a plug-and-play solution: a simulation study of a machine learning algorithm for acute leukaemia subtype diagnosis.

Pucher G, Rostalski T, Nensa F, Kleesiek J, Reinhardt H, Sauer C EBioMedicine. 2024; 111():105526.

PMID: 39721215 PMC: 11732467. DOI: 10.1016/j.ebiom.2024.105526.

Modeling intratumor heterogeneity in breast cancer.

McDonough E, Barroso M, Ginty F, Corr D Biofabrication. 2024; 17(1.

PMID: 39642392 PMC: 11740194. DOI: 10.1088/1758-5090/ad9b50.

References

Chowell D, Yoo S, Valero C, Pastore A, Krishna C, Lee M . Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021; 40(4):499-506. PMC: 9363980. DOI: 10.1038/s41587-021-01070-8. View

Davoli T, Uno H, Wooten E, Elledge S . Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017; 355(6322). PMC: 5592794. DOI: 10.1126/science.aaf8399. View

Alessi J, Price A, Richards A, Ricciuti B, Wang X, Elkrief A . Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. J Immunother Cancer. 2023; 11(11). PMC: 10626762. DOI: 10.1136/jitc-2023-007618. View

Spurr L, Martinez C, Kang W, Chen M, Zha Y, Hseu R . Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022; 3(12):1498-1512. DOI: 10.1038/s43018-022-00467-x. View

Girish V, Lakhani A, Thompson S, Scaduto C, Brown L, Hagenson R . Oncogene-like addiction to aneuploidy in human cancers. Science. 2023; 381(6660):eadg4521. PMC: 10753973. DOI: 10.1126/science.adg4521. View

Spurr L, Weichselbaum R, Pitroda S . Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022; 54(12):1782-1785. DOI: 10.1038/s41588-022-01235-4. View

Liu L, Bai X, Wang J, Tang X, Wu D, Du S . Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. Clin Cancer Res. 2019; 25(24):7413-7423. DOI: 10.1158/1078-0432.CCR-19-0558. View

Spurr L, Touat M, Taylor A, Dubuc A, Shih J, Meredith D . Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2020; 37(16):2461-2463. PMC: 8388019. DOI: 10.1093/bioinformatics/btaa980. View

Weichselbaum R, Liang H, Deng L, Fu Y . Radiotherapy and immunotherapy: a beneficial liaison?. Nat Rev Clin Oncol. 2017; 14(6):365-379. DOI: 10.1038/nrclinonc.2016.211. View

10.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

11.

Alessi J, Wang X, Elkrief A, Ricciuti B, Li Y, Gupta H . Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023; 18(11):1524-1537. PMC: 10913104. DOI: 10.1016/j.jtho.2023.05.019. View